The trial results support Tukysa-Herceptin-Perjeta as yet another option for breast cancer patients in the frontline ...

Pfizer's oral HER2 inhibitor Tukysa looks poised to find a new role as first-line maintenance therapy for HER2-positive ...

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

Pfizer has rolled out detailed trial data suggesting Tukysa could be part of a new first-line treatment to delay the progression of HER2-positive breast cancer. | Pfizer has rolled out detailed trial ...

Daiichi Sankyo has announced the dosing of first patient in the DESTINY-Ovarian01 Phase III trial’s randomisation phase, ...

In the January 2025 presentation, Jazz Pharmaceuticals expects zanidatamab to potentially receive approval and be launched as ...

Long a quieter, locally focused industry, Japanese pharma giants are increasingly looking to the rest of the world for deals.

Patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancers had similar progression-free survival (PFS) whether they were treated with sacituzumab govitecan-hziy (Trodelvy) or ...

AstraZeneca PLC (NASDAQ:AZN) operates across global healthcare markets through advanced research pathways, biopharmaceutical ...

Ovarian01 Phase 3 Trial of ENHERTU® Initiated as First-Line Maintenance Therapy in Patients with HER2 Expressing Advanced ...

The first patient has been dosed in the randomization phase of the DESTINY-Ovarian01 phase 3 trial evaluating Enhertu in combination with ...

Daiichi Sankyo showcases strength of industry-leading ADC portfolio with latest research updates from five landmark breast cancer trials at SABCS: Tokyo Tuesday, December 9, 2025, ...